Morgan Stanley’s TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK TRIV Stock Holding History

Morgan Stanley’s Portfolio TRIV Stock Details TRIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,560	Closed	-$30K	–	6958
2015 Q4	$30K	Sell	4,560 -15,064	-77%	-$99.9K	﹤0.01%	5909
2015 Q3	$99K	Sell	19,624 -4,460	-19%	-$24K	﹤0.01%	5428
2015 Q2	$129K	Buy	24,084 +1,273	+6%	+$9.03K	﹤0.01%	5457
2015 Q1	$239K	Buy	22,811 +21,334	+1,444%	+$220K	﹤0.01%	5118
2014 Q4	$19K	Buy	1,477 +594	+67%	+$8.1K	﹤0.01%	6072
2014 Q3	$13K	Sell	883 -29,081	-97%	-$422K	﹤0.01%	6132
2014 Q2	$466K	Buy	+29,964	New	+$455K	﹤0.01%	4630

Morgan Stanley's TRIV Position: Q1 2016 in Review

Morgan Stanley sold out of TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK (TRIV) in Q1 2016, closing a stake of 4,560 shares — an estimated $30K sold.

Morgan Stanley first reported a position in TRIV in Q2 2014 and held it in 7 quarters. The position peaked at $466K in Q2 2014. 0 funds tracked by Wall St. Rank hold TRIV as of Q1 2016.

Morgan Stanley reported no remaining TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position as of Q1 2016 after selling out during the quarter.
Morgan Stanley sold 4,560 TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK shares in Q1 2016, an estimated $30K.
Morgan Stanley first reported a position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK in Q2 2014 and held it in 7 quarters.
Morgan Stanley's TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position peaked at $466K in Q2 2014.
0 funds tracked by Wall St. Rank held TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK as of Q1 2016.

Based on Morgan Stanley's 13F filing for Q1 2016, filed 12 May 2016.